Does the media favor TVTX or VTRS?

In the previous week, Viatris had 2 more articles in the media than Travere Therapeutics. MarketBeat recorded 10 mentions for Viatris and 8 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.35 beat Viatris' score of 0.92 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TVTX or GMAB?

In the previous week, Travere Therapeutics had 4 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Travere Therapeutics and 4 mentions for Genmab A/S. Travere Therapeutics' average media sentiment score of 1.35 beat Genmab A/S's score of 0.95 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ASND or TVTX?

In the previous week, Travere Therapeutics had 5 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 8 mentions for Travere Therapeutics and 3 mentions for Ascendis Pharma A/S. Travere Therapeutics' average media sentiment score of 1.35 beat Ascendis Pharma A/S's score of 0.00 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TVTX or BBIO?

In the previous week, Travere Therapeutics had 4 more articles in the media than BridgeBio Pharma. MarketBeat recorded 8 mentions for Travere Therapeutics and 4 mentions for BridgeBio Pharma. Travere Therapeutics' average media sentiment score of 1.35 beat BridgeBio Pharma's score of 0.13 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TVTX or ELAN?

In the previous week, Travere Therapeutics had 5 more articles in the media than Elanco Animal Health. MarketBeat recorded 8 mentions for Travere Therapeutics and 3 mentions for Elanco Animal Health. Travere Therapeutics' average media sentiment score of 1.35 beat Elanco Animal Health's score of 1.10 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Travere Therapeutics (TVTX) Competitors

$57.85 +0.37 (+0.64%)

Closing price 04:00 PM Eastern

Extended Trading

$58.23 +0.38 (+0.66%)

As of 05:57 PM Eastern

Compare

TVTX vs. VTRS, GMAB, ASND, BBIO, and ELAN

Should you buy Travere Therapeutics stock or one of its competitors? MarketBeat compares Travere Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Travere Therapeutics include Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Travere Therapeutics compare to Viatris?

Travere Therapeutics (NASDAQ:TVTX) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

79.9% of Viatris shares are held by institutional investors. 4.4% of Travere Therapeutics shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Viatris had 2 more articles in the media than Travere Therapeutics. MarketBeat recorded 10 mentions for Viatris and 8 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.35 beat Viatris' score of 0.92 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, Viatris has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Travere Therapeutics currently has a consensus price target of $52.08, suggesting a potential downside of 9.97%. Viatris has a consensus price target of $17.50, suggesting a potential upside of 3.18%. Given Viatris' higher possible upside, analysts clearly believe Viatris is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Viatris has a net margin of -2.04% compared to Travere Therapeutics' net margin of -4.00%. Viatris' return on equity of 19.04% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Viatris	-2.04%	19.04%	7.62%

Travere Therapeutics has higher earnings, but lower revenue than Viatris. Travere Therapeutics is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	10.96	-$25.55M	-$0.23	N/A
Viatris	$14.30B	1.38	-$3.51B	-$0.26	N/A

Summary

Travere Therapeutics and Viatris tied by winning 8 of the 16 factors compared between the two stocks.

How does Travere Therapeutics compare to Genmab A/S?

Travere Therapeutics (NASDAQ:TVTX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Genmab A/S has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	10.96	-$25.55M	-$0.23	N/A
Genmab A/S	$3.72B	4.89	$963M	$1.32	22.11

7.1% of Genmab A/S shares are owned by institutional investors. 4.4% of Travere Therapeutics shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Travere Therapeutics presently has a consensus price target of $52.08, suggesting a potential downside of 9.97%. Genmab A/S has a consensus price target of $38.21, suggesting a potential upside of 30.96%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts plainly believe Genmab A/S is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Travere Therapeutics had 4 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Travere Therapeutics and 4 mentions for Genmab A/S. Travere Therapeutics' average media sentiment score of 1.35 beat Genmab A/S's score of 0.95 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

Genmab A/S has a net margin of 21.05% compared to Travere Therapeutics' net margin of -4.00%. Genmab A/S's return on equity of 15.34% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Genmab A/S	21.05%	15.34%	8.94%

Summary

Genmab A/S beats Travere Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Ascendis Pharma A/S presently has a consensus target price of $295.67, suggesting a potential upside of 10.75%. Travere Therapeutics has a consensus target price of $52.08, suggesting a potential downside of 9.97%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ascendis Pharma A/S is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Travere Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Travere Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	20.44	-$258M	$8.67	30.79
Travere Therapeutics	$490.73M	10.96	-$25.55M	-$0.23	N/A

Ascendis Pharma A/S has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

In the previous week, Travere Therapeutics had 5 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 8 mentions for Travere Therapeutics and 3 mentions for Ascendis Pharma A/S. Travere Therapeutics' average media sentiment score of 1.35 beat Ascendis Pharma A/S's score of 0.00 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 57.87% compared to Travere Therapeutics' net margin of -4.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

Summary

Ascendis Pharma A/S beats Travere Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Travere Therapeutics compare to BridgeBio Pharma?

Travere Therapeutics (NASDAQ:TVTX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Travere Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Travere Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	10.96	-$25.55M	-$0.23	N/A
BridgeBio Pharma	$502.08M	30.39	-$724.93M	-$3.74	N/A

In the previous week, Travere Therapeutics had 4 more articles in the media than BridgeBio Pharma. MarketBeat recorded 8 mentions for Travere Therapeutics and 4 mentions for BridgeBio Pharma. Travere Therapeutics' average media sentiment score of 1.35 beat BridgeBio Pharma's score of 0.13 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.9% of BridgeBio Pharma shares are held by institutional investors. 4.4% of Travere Therapeutics shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Travere Therapeutics has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Travere Therapeutics has a net margin of -4.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Travere Therapeutics presently has a consensus price target of $52.08, suggesting a potential downside of 9.97%. BridgeBio Pharma has a consensus price target of $92.90, suggesting a potential upside of 19.24%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

BridgeBio Pharma beats Travere Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Travere Therapeutics compare to Elanco Animal Health?

Travere Therapeutics (NASDAQ:TVTX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Travere Therapeutics has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

In the previous week, Travere Therapeutics had 5 more articles in the media than Elanco Animal Health. MarketBeat recorded 8 mentions for Travere Therapeutics and 3 mentions for Elanco Animal Health. Travere Therapeutics' average media sentiment score of 1.35 beat Elanco Animal Health's score of 1.10 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.5% of Elanco Animal Health shares are owned by institutional investors. 4.4% of Travere Therapeutics shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Travere Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Travere Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	10.96	-$25.55M	-$0.23	N/A
Elanco Animal Health	$4.72B	2.61	-$232M	-$0.50	N/A

Travere Therapeutics has a net margin of -4.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Elanco Animal Health	-4.95%	7.42%	3.66%

Travere Therapeutics presently has a consensus target price of $52.08, suggesting a potential downside of 9.97%. Elanco Animal Health has a consensus target price of $28.55, suggesting a potential upside of 15.85%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

Elanco Animal Health beats Travere Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Travere Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVTX vs. The Competition

Export

Metric	Travere Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.35B	$3.74B	$7.10B	$12.57B
Dividend Yield	N/A	2.17%	2.67%	6.89%
P/E Ratio	-251.51	21.69	27.19	24.43
Price / Sales	10.96	329.72	578.09	116.19
Price / Cash	158.73	147.73	49.34	57.41
Price / Book	45.20	8.49	10.95	6.40
Net Income	-$25.55M	$23.68M	$3.56B	$331.37M
7 Day Performance	1.83%	2.04%	1.77%	-0.48%
1 Month Performance	26.28%	14.28%	6.65%	3.39%
1 Year Performance	296.23%	67.81%	36.06%	24.97%

Travere Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVTX Travere Therapeutics	2.0844 of 5 stars	$57.85 +0.6%	$52.08 -10.0%	+283.2%	$5.35B	$490.73M	N/A	460	Positive News
VTRS Viatris	2.8999 of 5 stars	$16.94 +1.4%	$17.50 +3.3%	+81.6%	$19.71B	$14.56B	N/A	30,000
GMAB Genmab A/S	4.797 of 5 stars	$28.12 -1.4%	$38.21 +35.9%	+37.2%	$17.51B	$3.90B	21.27	3,029	News Coverage Gap Up
ASND Ascendis Pharma A/S	3.751 of 5 stars	$270.22 -1.6%	$295.39 +9.3%	+53.9%	$16.83B	$814.57M	31.13	1,189	Analyst Upgrade
BBIO BridgeBio Pharma	2.7945 of 5 stars	$78.89 +2.2%	$92.90 +17.8%	+77.9%	$15.46B	$579.96M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVTX) was last updated on 7/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Travere Therapeutics (TVTX) Competitors

TVTX vs. VTRS, GMAB, ASND, BBIO, and ELAN

How does Travere Therapeutics compare to Viatris?

Summary

How does Travere Therapeutics compare to Genmab A/S?

Summary

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Travere Therapeutics compare to BridgeBio Pharma?

Summary

How does Travere Therapeutics compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX vs. The Competition

Travere Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Travere Therapeutics (TVTX) Competitors

TVTX vs. VTRS, GMAB, ASND, BBIO, and ELAN

How does Travere Therapeutics compare to Viatris?

Do institutionals & insiders have more ownership in TVTX or VTRS?

Does the media favor TVTX or VTRS?

Which has more volatility & risk, TVTX or VTRS?

Do analysts prefer TVTX or VTRS?

Is TVTX or VTRS more profitable?

Which has higher valuation & earnings, TVTX or VTRS?

Summary

How does Travere Therapeutics compare to Genmab A/S?

Which has higher earnings & valuation, TVTX or GMAB?

Do insiders and institutionals hold more shares of TVTX or GMAB?

Do analysts prefer TVTX or GMAB?

Does the media refer more to TVTX or GMAB?

Which has more risk & volatility, TVTX or GMAB?

Is TVTX or GMAB more profitable?

Summary

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Do analysts prefer ASND or TVTX?

Which has higher valuation & earnings, ASND or TVTX?

Which has more risk & volatility, ASND or TVTX?

Does the media favor ASND or TVTX?

Is ASND or TVTX more profitable?

Summary

How does Travere Therapeutics compare to BridgeBio Pharma?

Which has preferable valuation & earnings, TVTX or BBIO?

Does the media prefer TVTX or BBIO?

Do insiders & institutionals hold more shares of TVTX or BBIO?

Which has more volatility & risk, TVTX or BBIO?

Is TVTX or BBIO more profitable?

Do analysts rate TVTX or BBIO?

Summary

How does Travere Therapeutics compare to Elanco Animal Health?

Which has more risk and volatility, TVTX or ELAN?

Does the media prefer TVTX or ELAN?

Do insiders & institutionals hold more shares of TVTX or ELAN?

Which has stronger valuation & earnings, TVTX or ELAN?

Is TVTX or ELAN more profitable?

Do analysts prefer TVTX or ELAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX vs. The Competition

Travere Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools